Shop

Author at Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Press Releases

24 Mar 2021

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

By Microdose

Press Releases

23 Mar 2021

New Wave Subsidiary, N2 Logics, Commences Phase Two of Way of Will’s E-commerce Optimization

TORONTO, March 23, 2021 /CNW/ - NEW WAVE HOLDINGS CORP....

By Microdose

Press Releases

23 Mar 2021

Mindset Pharma and InterVivo Solutions to Jointly Develop Advanced Cooperative Psychedelics Evaluation Platform (“Cope”); Cope Expected to Be World’s First in Vivo Psychedelic Benchmark Data Set

Toronto, Ontario–(Newsfile Corp....

By Microdose

Press Releases

23 Mar 2021

NeonMind CEO Provides Update on the Progress of its Psilocybin Drug Development Research Plan and Team

Vancouver, British Columbia–(Newsfile Corp....

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Press Releases

19 Mar 2021

Numinus Announces Closing of $40-Million Bought Deal Financing

/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC, March...

By Microdose

Press Releases

19 Mar 2021

Revive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of International Patent Application

TORONTO, March 19, 2021 – Revive Therapeutics Ltd....

By Microdose

Press Releases

19 Mar 2021

Havn Life CEO to Present at Zooming With LD, a Leading Platform for Microcap Companies

CEO Tim Moore will appear on Tuesday, March 24th at 8:00 AM PT/ 11:00 AM ET Vancouver, BC – Havn Life Sciences Inc....

By Microdose

Press Releases

18 Mar 2021

Pure Extracts Orders Cutting Edge Vitalis Cosolvent Injection System

VANCOUVER, British Columbia, March 18, 2021 (GLOBE NEWSWIRE) — Pure Extracts Technologies Corp....

By Microdose

Press Releases

18 Mar 2021

New Wave Subsidiary, Way of Will Inc., Receives Purchase Order for Foot & Shoe Deodorant from Fitness Subscription Service Gainz Box

TORONTO, March 18, 2021 /CNW/ – NEW WAVE HOLDINGS CORP....

By Microdose

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.